Rani Therapeutics Holdings Inc Cash Flow Conversion Efficiency
Rani Therapeutics Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) has a cash flow conversion efficiency ratio of -0.188x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.03 Million) by net assets ($47.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rani Therapeutics Holdings Inc (2019–2025)
Cash flow conversion efficiency of Rani Therapeutics Holdings Inc from 2019 to 2025. This chart illustrates how Rani Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Rani Therapeutics Holdings Inc share price for real-time trading data and today's change.
Rani Therapeutics Holdings Inc Cash Flow Conversion Ratio Explained
Rani Therapeutics Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rani Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rani Therapeutics Holdings Inc ranked by their cash flow conversion efficiency. Also see Rani Therapeutics Holdings Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cayman Engley Industrial Co
TW:2239
|
0.033x |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
0.079x |
|
Canyon Resources Ltd
AU:CAY
|
-0.257x |
|
BEST SPAC I Acquisition Corp. Class A Ordinary Shares
NASDAQ:BSAA
|
-0.070x |
|
Castellum Inc.
NYSE MKT:CTM
|
0.036x |
|
Gentian Diagnostics AS
OL:GENT
|
0.208x |
|
Export Packing
KO:002200
|
0.002x |
|
Alpha Pro Tech Ltd
NYSE MKT:APT
|
0.000x |
Annual Cash Flow Conversion Efficiency for Rani Therapeutics Holdings Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rani Therapeutics Holdings Inc from 2019 to 2025. Review Rani Therapeutics Holdings Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $41.51 Million | $-18.71 Million | -0.451x | +95.56% |
| 2024-12-31 | $3.49 Million | $-35.50 Million | -10.162x | -404.63% |
| 2023-12-31 | $25.44 Million | $-51.24 Million | -2.014x | -220.38% |
| 2022-12-31 | $74.00 Million | $-46.52 Million | -0.629x | -136.97% |
| 2021-12-31 | $121.57 Million | $-32.24 Million | -0.265x | -300.95% |
| 2020-12-31 | $-113.34 Million | $-14.96 Million | 0.132x | -51.44% |
| 2019-12-31 | $-96.64 Million | $-26.27 Million | 0.272x | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more